Investigation of Cogane (PYM50028) in Early-stage Parkinson's Disease (CONFIDENT-PD)
Status: | Archived |
---|---|
Conditions: | Parkinsons Disease |
Therapuetic Areas: | Neurology |
Healthy: | No |
Age Range: | Any |
Updated: | 7/1/2011 |
Start Date: | November 2010 |
End Date: | December 2012 |
Phase II, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of PYM50028 in Subjects With Early-stage Parkinson's Disease Administered Once Daily for 28 Weeks
A study to test the therapeutic benefit of the compound PYM50028, versus placebo, in
treating early-stage Parkinson's disease. Therapeutic benefit will be assessed using the
Unified Parkinson's Disease Rating Scale (UPDRS). It is hypothesised that PYM50028 will be
safe and well tolerated in this study and demonstrate therapeutic benefit in this patient
population.
We found this trial at
9
sites
Click here to add this to my saved trials

Northwestern University Northwestern is recognized both nationally and internationally for the quality of its educational...
Click here to add this to my saved trials

North Shore University Hospital North Shore-LIJ Health System includes 16 award-winning hospitals and nearly 400...
Click here to add this to my saved trials

Washington University Washington University creates an environment to encourage and support an ethos of wide-ranging...
Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials
